Prollenium Adds RENEW™+ Skin Booster to the REVANESSE® Collection
The product marks a new era for dermal injections with long-lasting hydration to improve skin quality from the inside out.
Article content
Article content
RICHMOND HILL, Ontario — Prollenium, a global leader in medical aesthetic technology, launches Renew™+ to the Revanesse ® family of dermal fillers in Canada. Available immediately, Revanesse® Renew™+ is a unique skin booster that combines low and high molecular weight hyaluronic acid (HA) to hydrate and rejuvenate the skin below the surface, improving skin texture and creating a smoother, more radiant appearance.
Article content
Unlike traditional fillers, Revanesse® Renew™+ is a skin-boosting injection made with 100% high-purity, non-cross-linked HA with a low viscosity and easy spreadability. It is ideal for improving skin quality. Injected into the top layers of skin on the face, neck, or chest, it attracts and retains water molecules, adding an extra moisture boost for a refreshed and renewed look.
Article content
'Renew™+ is a first-of-its-kind dermal filler made in Canada and continues the tradition of breakthrough innovations for the family of Revanesse® products,' said Tim Lee, Chief Scientific Officer of Prollenium. Revanesse® Renew™+ marks the next generation of dermal injections, using the latest technology and advancements to create a lasting solution that leaves patients glowing and rejuvenated.
Article content
The Revanesse® family of dermal fillers features multi-purpose HA-based dermal fillers that provide real results instantly with a quick, minimally invasive beauty treatment. Revanesse® Renew+™ penetrates deeply to hydrate from within, reducing the appearance of fine lines and wrinkles for smoother, plumper skin. Works on the skin's surface to firm, tone, and lock in moisture for a more lifted, youthful look.
Article content
'At Prollenium, we're committed to creating top-of-the-line products to help health care providers give patients the refreshed look they've always wanted,' said Walter Geiger, acting CEO of Prollenium. 'This latest product in the Revanesse® line underscores our dedication to equipping providers with the latest technology and advancements in the medical aesthetics industry.'
Article content
Revanesse® Renew™+ is administered via microinjections into the superficial dermis using fine gauge needles, spaced evenly, 1 cm apart across the desired treatment area. For optimal results, it is recommended to have 2 treatments at 4 weeks apart.
Article content
About Prollenium
Prollenium leads the way in facial aesthetics and rejuvenation technology, turning complex science into reliable, effective products. As the first FDA-approved dermal filler manufacturer in North America, Prollenium redefines standards with cutting-edge innovation, exceptional safety, and a portfolio tailored to patient needs.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
5 hours ago
- Toronto Star
Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
Exton, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) — Lungpacer Medical Inc., a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-on Payment (NTAP) status for the AeroPace® System under the Fiscal Year 2026 Inpatient Prospective Payment System (IPPS) Final Rule, effective October 1, 2025. The AeroPace® System is an FDA-designated breakthrough device that uses periodic neurostimulation to exercise the diaphragm, helping mechanically ventilated patients to breathe independently faster. Clinical evidence shows that patients treated with the AeroPace System strengthened their diaphragm by 50%, reduced their risk of being on the ventilator for 30 days by 35%, and reduced ventilator time by 3 days when compared to standard of care.
Cision Canada
a day ago
- Cision Canada
BTL Expands EMFACE® Indications with New FDA Clearance for TMJ Dysfunction
BOSTON, Aug. 13, 2025 /CNW/ -- BTL Industries, a global leader in medical and wellness technologies, has expanded the FDA-cleared applications of its EMFACE® platform with a new indication for the treatment of temporomandibular joint (TMJ) dysfunction. EMFACE® is now cleared by the FDA for the relief of symptoms associated with muscle spasm, treatment of TMJ dysfunction and associated pain, muscle re-education, increased local blood flow, and the maintenance or improvement of mandibular range of motion. Developed through years of research and engineering, EMFACE combines synchronized radiofrequency and HIFES® technology for facial muscle stimulation, delivering relief without surgery, injections, or medication. "EMFACE is an established technology platform with multiple FDA-cleared uses," said David Chmel, CEO of BTL Industries. "This new indication allows dental, oral health, and wellness providers to address TMJ dysfunction within its approved uses, expanding the benefits of EMFACE to more patients." "TMJ dysfunction impacts more than the jaw — it affects quality of life," said Shireen Dhanani, DMD, Leesburg, FL. "With EMFACE, we can now offer an accessible, non-invasive option that not only helps patients find relief and functional improvement, but also expands the scope of dental care." BTL continues to redefine what's possible in facial care and wellness, bringing science-backed technologies like EMFACE into new areas of medicine to improve lives and advance patient care worldwide. For more information about EMFACE, visit www. About BTL Industries Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. Operating in over 90 countries, BTL holds more than 200 patents and employs over 500 R&D engineers dedicated to advancing medical treatments through technology and science. Its product portfolio includes EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others.
Cision Canada
a day ago
- Cision Canada
New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team
MINNEAPOLIS, Aug. 13, 2025 /CNW/ -- A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all personnel in the catheterization lab from scatter radiation. The findings show that while other next-generation systems offer protection for the primary operator and assistant, the EggNest™ Complete system provides significant protection for the entire interventional team. The study, titled "Comparative Effectiveness of 2 Next-Generation Scatter Radiation Shielding Systems," compared the EggNest™ Complete system with the Rampart IC system and a no-shielding condition using an anthropomorphic phantom. The results showed that both the EggNest™ Complete and Rampart IC systems significantly reduced radiation exposure for the operator and assistant positions compared to no shielding. However, the EggNest™ Complete system provided additional significant protection for staff at the head of the bed and the nursing positions, a benefit not observed with the Rampart IC system. "From the beginning, Egg Medical has had three guiding principles: we need to protect the entire team from scatter radiation, we can't interfere with workflow or patient access, and the reduction in radiation exposure must be nearly complete. The study by Riley et al shows very clearly that the EggNest Complete system dramatically reduces radiation exposure for everyone in the room, and that the operator and assistant are almost completely protected. That is a marked improvement to safety for everyone who works in x-ray guided procedures," said Dr. Robert Wilson, CEO of Egg Medical. The study's authors note that interventional cardiology procedures expose healthcare professionals to prolonged ionizing radiation, which poses significant health risks including heightened rates of malignancy, cataracts, and orthopedic injuries. Traditional lead aprons, while offering some protection, are heavy (up to 25 pounds) and can lead to musculoskeletal injuries. A recent SCAI survey found that 66% of operators reported musculoskeletal pain attributed to their time in the cardiac catheterization laboratory. "It's a community effort to bring the issue of healthcare worker safety to the forefront of our industry. We deserve the same level of protection we strive to give to patients. This study highlights that Egg Medical's EggNest Complete System sets a new standard for what ALARA (As Low As Reasonably Achievable) means today," said Robert Riley, MD, a co-author of the study. The study's findings indicate that a comprehensive shielding system like EggNest™ Complete is crucial for ensuring the safety of all interventional lab personnel, including operators, assistants, nurses, and other staff. This is particularly important for complex procedures where staff may be positioned in areas with limited traditional shielding and higher cumulative exposure. The authors of a separate commentary on the study commended the findings, emphasizing that these results align with the Society for Cardiovascular Angiography & Interventions' mission to advance occupational safety and are essential for sustaining the interventional cardiology workforce. Comparative Effectiveness of 2 Next-Generation Scatter Radiation Shielding Systems. Stephen Kidd, MD, Robert F. Riley, MD, MS, Juliette Power, MD, Brian Stegman, MD, Thom G. Dahle, MD. Division of Cardiology, Overlake Medical Center, Bellevue, Washington. Division of Cardiology, St. Cloud Hospital, St. Cloud, Minnesota. Journal of the Society for Cardiovascular Angiography & Interventions (2025), doi: About Egg Medical Egg Medical is a global leader in radiation protection technologies. Headquartered in Minnesota, the company was founded with the goal to reduce the scatter radiation exposure of physicians, surgeons, nurses, technicians and others who use x-ray imaging to perform life-saving diagnostic and therapeutic procedures for patients. More information about Egg Medical is available at
